Clinical Trials Logo

Appendix Carcinoma clinical trials

View clinical trials related to Appendix Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05472948 Recruiting - Metastatic Clinical Trials

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maximum tolerant dose or recommended II research dose of Surufatinib combined with a fixed dose of Sintilimab and Capecitabine using 3 + 3 dose climbing experiment.